Celldex Therapeutics (CLDX) Net Cash Flow (2010 - 2026)

Celldex Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 161.02% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $18.6 million (up 118.97% YoY), while the FY2025 annual figure was $515000.0, up 107.97% from the prior year.
• Net Cash Flow for Q1 2026 stood at $6.8 million, up from -$7.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $80.3 million in Q1 2024, with the low at -$72.3 million in Q2 2024.
• The 5-year median for Net Cash Flow is -$6.3 million (2024), against an average of -$201529.4.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow plunged 933.3% in 2023, then soared 305.02% in 2025.
• Celldex Therapeutics' Net Cash Flow stood at $10.8 million in 2022, then rose by 26.13% to $13.7 million in 2023, then sank by 158.79% to -$8.0 million in 2024, then climbed by 10.84% to -$7.2 million in 2025, then jumped by 195.47% to $6.8 million in 2026.
• Business Quant data shows CLDX's Net Cash Flow at $6.8 million in Q1 2026, -$7.2 million in Q4 2025, and $13.0 million in Q3 2025.